According to a new market research report "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020", published by MarketsandMarkets, The U.S. General Anesthesia Drugs Market is expected to reach around $2 Billion by 2020 at a CAGR of 3.8% from 2015 to 2020.

Browse 42 market data Tables and 28 Figures spread through 114 Pages and in-depth TOC on "U.S. General Anesthesia Drugs Market"

http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

Early buyers will receive 10% customization on this report.

The U.S. general anesthesia drugs market is poised to reach ~ USD 2.0 billion by 2020 from USD 1.6 billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

Ask for PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=713


The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Major players operating in the U.S. General Anesthesia Drugs Market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: [email protected]